Novel stereoselective syntheses of the fused benzazepine dopamine D1 antagonist (6aS,13bR)-11-chloro-6,6a,7,8,9,13b-hexahydro-7-methy-5H-benzo[d]naphth[2,1-b]azepin-12-ol (Sch 39166):: 1.: Aziridinium salt based syntheses

被引:23
作者
Draper, RW
Hou, D
Iyer, R
Lee, GM
Liang, JT
Mas, JL
Tormos, W
Vater, EJ
机构
[1] Schering Plough Corp, Res Inst, Chem Proc Res & Dev Dept, Kenilworth, NJ 07033 USA
[2] Werthenstein Chem AG, Chem Dev Dept, CH-6105 Schachen, Switzerland
关键词
D O I
10.1021/op970121s
中图分类号
O69 [应用化学];
学科分类号
081704 [应用化学];
摘要
Several novel enantioselective syntheses of the dopamine D-1 antagonist (6aS,13bR)-11-chloro-6,6a,7,8,9,13b-hexahydro-7- methyl-5H-benzo[d]naphth[2,1-b]azepin-12-ol (2) are described in which the key intermediate was 1-(2,2 dimethoxyethyl)-1-methyl-1a,2,3,7b-tetrahydro-1H-naphth[1,2-b] aziridinium salt (20), The latter species was prepared either from 1-(2,2-dimethoxyethyl)-1a,2,3,7b-tetrahydro-]H-naphth[1,2-b]- azirine (18) by methylation or from the tertiary amino alcohols 1-[(2,2-dimethoxyethyl)methylamino]-1,2,3,4-tetrahydro-2 -naphthalenol (23) or 2-[(2,2-dimethoxyethyl)methylamino]-1,2,3,4-tetrahydro -1-naphthalenol (24) by tosylation and in situ ring closure. Regioselective trapping of 20 with Grignard reagent (4-chloro-3-methoxyphenyl)magnesium bromide (10) then afforded the transamine 1-(4-chloro-3-methoxyphenyl)-N-(2,2-dimethoxyethyl)-1,2,3,4 -tetrahydro-N-methyl-2-naphth-alenamine (22), which was cyclized to give 11-chloro-6,6a,7,8,9,13b-hexahydro-7-methyl-12-methoxy-5H-benzo [d]- naphth[2,1-b]azepine (9), a known precursor of 2, Several enantioselective syntheses, including a Jacobsen epoxidation route, a de novo synthesis from L-homophenylalanine, and a classical salt resolution sequence, were developed for the preparation of the key intermediates in chiral form.
引用
收藏
页码:175 / 185
页数:11
相关论文
共 44 条
[1]
BACH RD, 1981, ORG SYNTH, V60, P63
[2]
BARNETT A, 1986, Drugs of the Future, V11, P49
[3]
BERGER J, 1990, Patent No. 354686
[4]
SYNTHESIS AND RECEPTOR AFFINITIES OF SOME CONFORMATIONALLY RESTRICTED ANALOGS OF THE DOPAMINE D1 SELECTIVE LIGAND (5R)-8-CHLORO-2,3,4,5-TETRAHYDRO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL [J].
BERGER, JG ;
CHANG, WK ;
CLADER, JW ;
HOU, D ;
CHIPKIN, RE ;
MCPHAIL, AT .
JOURNAL OF MEDICINAL CHEMISTRY, 1989, 32 (08) :1913-1921
[5]
BERGER JG, 1987, Patent No. 230270
[6]
CHIPKIN RE, 1988, J PHARMACOL EXP THER, V247, P1093
[7]
H-1-NMR SPECTRA AND THE STRUCTURE OF THE PRODUCTS OF REACTION BETWEEN TRANS-1-N-ALKYLAMINOTETRALIN-2-OLS, TRANS-3-N-ALKYLAMINOTETRALIN-2-OLS AND FORMALDEHYDE [J].
CRABB, TA ;
ROBINSON, P .
MAGNETIC RESONANCE IN CHEMISTRY, 1986, 24 (09) :798-802
[8]
BROMOHYDRIN FORMATION IN DIMETHYL SULFOXIDE [J].
DALTON, DR ;
DUTTA, VP ;
JONES, DC .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1968, 90 (20) :5498-&
[9]
ARYL-SUBSTITUTED DIALKOXYCARBONIUM IONS AS ALKYLATING AGENTS [J].
DIMROTH, K ;
HEINRICH, P .
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 1966, 5 (07) :676-&
[10]
Novel stereoselective syntheses of the fused benzazepine dopamine D1 antagonist (6aS,13bR)-11-chloro-6,6a,7,8,9,13b-hexahydro-7-methyl-5H-benzo[d]naphth[2,1-b]azepin-12-ol (Sch 39166):: 2.: L-homophenylalanine-based syntheses [J].
Draper, RW ;
Hou, D ;
Iyer, R ;
Lee, GM ;
Liang, JT ;
Mas, JL ;
Vater, EJ .
ORGANIC PROCESS RESEARCH & DEVELOPMENT, 1998, 2 (03) :186-193